{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T02:42:03Z","timestamp":1782873723702,"version":"3.54.5"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Genentech, United States"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>The aim of this study was to assess the impact of diabetic retinopathy (DR) severity on the risk of DR progression to proliferative DR (PDR) or clinically significant macular edema (CSME) in patients with diabetes mellitus (DM).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This is a prospective, longitudinal, non-interventional, and observational cohort study of patients with DM in the United States based on a database of 7-field color fundus photograph images from primary care visits. Study participants were adults aged\u2009\u2265\u200918 years who underwent DR screening in either eye between January 1999 and December 2016. DR severity was graded according to the Early Treatment Diabetic Retinopathy Study-Diabetic Retinopathy Severity Scale (ETDRS-DRSS) on 7-field color fundus photographs. The main outcomes were \u2265\u20092-step DR worsening and development of CSME, PDR, or CSME and PDR together.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>For all 41,977 eyes evaluated, the proportion of eyes with \u2265\u20092-step DR worsening was 2.7% at year 2 and 9.6% at year 5. Rate of \u2265\u20092-step DR worsening was greatest among eyes with moderate-to-severe NPDR with baseline DRSS 43\u201353 (36.5% at year 5). Analysis of PDR and CSME outcomes showed the presence of 3 distinct clinical phenotypes: 1 subset progressed to CSME (1.24% at year 5), another to PDR (0.49% at year 5), and only a small subset progressed to both vision-threatening forms of DR (0.10% at year 5). The clinical phenotype did not appear to be dependent on baseline DRSS.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Overall, the risk of progression to vision-threatening forms of DR was more pronounced in eyes with moderate-to-severe non-proliferative DR at baseline. In addition, we found that distinct DR clinical subtypes progressing to either PDR and\/or CSME over a 5-year period are not driven by baseline DR severity, suggesting other factors may contribute.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12886-025-04307-1","type":"journal-article","created":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T14:01:25Z","timestamp":1759759285000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Progression of diabetic retinopathy in a longitudinal real-world study of patients in primary care"],"prefix":"10.1186","volume":"25","author":[{"given":"Geeta","family":"Lalwani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles C.","family":"Wykoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayla","family":"Briggs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chin-Yu","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Verena","family":"Steffen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zdenka","family":"Haskova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,6]]},"reference":[{"issue":"9","key":"4307_CR1","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.2337\/dc15-2171","volume":"39","author":"JL Leasher","year":"2016","unstructured":"Leasher JL, Bourne RR, Flaxman SR, Jonas JB, Keeffe J, Naidoo K, et al. Global estimates on the number of people blind or visually impaired by diabetic retinopathy: a meta-analysis from 1990 to 2010. Diabetes Care. 2016;39(9):1643\u20139.","journal-title":"Diabetes Care"},{"issue":"12","key":"4307_CR2","doi-asserted-by":"publisher","first-page":"e1221","DOI":"10.1016\/S2214-109X(17)30393-5","volume":"5","author":"SR Flaxman","year":"2017","unstructured":"Flaxman SR, Bourne RRA, Resnikoff S, Ackland P, Braithwaite T, Cicinelli MV, et al. Global causes of blindness and distance vision impairment 1990\u20132020: a systematic review and meta-analysis. Lancet Glob Health. 2017;5(12):e1221\u201334.","journal-title":"Lancet Glob Health"},{"issue":"2","key":"4307_CR3","doi-asserted-by":"publisher","first-page":"e144","DOI":"10.1016\/S2214-109X(20)30489-7","volume":"9","author":"GBD 2019 Blindness and Vision Impairment Collaborators; Vision Loss Expert Group of the Global Burden of Disease Study","year":"2021","unstructured":"GBD 2019 Blindness and Vision Impairment Collaborators; Vision Loss Expert Group of the Global Burden of Disease Study. Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the right to sight: an analysis for the Global Burden of Disease Study. Lancet Glob Health. 2021;9(2):e144\u201360.","journal-title":"Lancet Glob Health"},{"issue":"11","key":"4307_CR4","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1016\/j.ophtha.2021.04.027","volume":"128","author":"ZL Teo","year":"2021","unstructured":"Teo ZL, Tham YC, Yu M, Chee ML, Rim TH, Cheung N, et al. Global prevalence of diabetic retinopathy and projection of burden through 2045: systematic review and meta-analysis. Ophthalmology. 2021;128(11):1580\u201391.","journal-title":"Ophthalmology"},{"key":"4307_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2016.12","volume":"2","author":"TY Wong","year":"2016","unstructured":"Wong TY, Cheung CM, Larsen M, Sharma S, Simo R. Diabetic retinopathy. Nat Rev Dis Primers. 2016;2:16012.","journal-title":"Nat Rev Dis Primers"},{"key":"4307_CR6","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.visres.2017.04.003","volume":"139","author":"J Lechner","year":"2017","unstructured":"Lechner J, O\u2019Leary OE, Stitt AW. The pathology associated with diabetic retinopathy. Vis Res. 2017;139:7\u201314.","journal-title":"Vis Res"},{"issue":"2","key":"4307_CR7","doi-asserted-by":"publisher","first-page":"112","DOI":"10.7861\/clinmed.2021-0792","volume":"22","author":"TH Fung","year":"2022","unstructured":"Fung TH, Patel B, Wilmot EG, Amoaku WM. Diabetic retinopathy for the non-ophthalmologist. Clin Med. 2022;22(2):112\u20136.","journal-title":"Clin Med"},{"issue":"7","key":"4307_CR8","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/s41581-020-0278-5","volume":"16","author":"JB Cole","year":"2020","unstructured":"Cole JB, Florez JC. Genetics of diabetes mellitus and diabetes complications. Nat Rev Nephrol. 2020;16(7):377\u201390.","journal-title":"Nat Rev Nephrol"},{"issue":"3","key":"4307_CR9","doi-asserted-by":"publisher","first-page":"556","DOI":"10.2337\/dc11-1909","volume":"35","author":"JW Yau","year":"2012","unstructured":"Yau JW, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski JW, Bek T, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012;35(3):556\u201364.","journal-title":"Diabetes Care"},{"issue":"10","key":"4307_CR10","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/j.oret.2018.06.005","volume":"2","author":"CC Wykoff","year":"2018","unstructured":"Wykoff CC, Eichenbaum DA, Roth DB, Hill L, Fung AE, Haskova Z. Ranibizumab induces regression of diabetic retinopathy in most patients at high risk of progression to proliferative diabetic retinopathy. Ophthalmol Retina. 2018;2(10):997\u20131009.","journal-title":"Ophthalmol Retina"},{"issue":"5 Suppl","key":"4307_CR11","first-page":"823","volume":"98","author":"Early Treatment Diabetic Retinopathy Study Research Group","year":"1991","unstructured":"Early Treatment Diabetic Retinopathy Study Research Group. Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Ophthalmology. 1991;98(5 Suppl):823\u201333.","journal-title":"Ophthalmology"},{"key":"4307_CR12","doi-asserted-by":"publisher","first-page":"4385","DOI":"10.2147\/OPTH.S286527","volume":"14","author":"J Zhang","year":"2020","unstructured":"Zhang J, Strauss EC. Sensitive detection of therapeutic efficacy with the ETDRS Diabetic Retinopathy Severity Scale. Clin Ophthalmol. 2020;14:4385\u201393.","journal-title":"Clin Ophthalmol"},{"issue":"9","key":"4307_CR13","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1001\/archophthalmol.2012.1043","volume":"130","author":"MS Ip","year":"2012","unstructured":"Ip MS, Domalpally A, Hopkins JJ, Wong P, Ehrlich JS. Long-term effects of ranibizumab on diabetic retinopathy severity and progression. Arch Ophthalmol. 2012;130(9):1145\u201352.","journal-title":"Arch Ophthalmol"},{"issue":"4","key":"4307_CR14","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1001\/archopht.119.4.547","volume":"119","author":"R Klein","year":"2001","unstructured":"Klein R, Klein BE, Moss SE. How many steps of progression of diabetic retinopathy are meaningful? The Wisconsin epidemiologic study of diabetic retinopathy. Arch Ophthalmol. 2001;119(4):547\u201353.","journal-title":"Arch Ophthalmol"},{"issue":"2","key":"4307_CR15","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/S0161-6420(98)93601-6","volume":"105","author":"MR Hee","year":"1998","unstructured":"Hee MR, Puliafito CA, Duker JS, Reichel E, Coker JG, Wilkins JR, et al. Topography of diabetic macular edema with optical coherence tomography. Ophthalmology. 1998;105(2):360\u201370.","journal-title":"Ophthalmology"},{"issue":"2","key":"4307_CR16","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1034\/j.1600-0420.1999.770221.x","volume":"77","author":"M Henricsson","year":"1999","unstructured":"Henricsson M, Sellman A, Tyrberg M, Groop L. Progression to proliferative retinopathy and macular oedema requiring treatment. Assessment of the alternative classification of the Wisconsin Study. Acta Ophthalmol Scand. 1999;77(2):218\u201323.","journal-title":"Acta Ophthalmol Scand"},{"issue":"5","key":"4307_CR17","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.ophtha.2017.01.003","volume":"124","author":"MS Ip","year":"2017","unstructured":"Ip MS, Zhang J, Ehrlich JS. The clinical importance of changes in Diabetic Retinopathy severity score. Ophthalmology. 2017;124(5):596\u2013603.","journal-title":"Ophthalmology"},{"issue":"14","key":"4307_CR18","doi-asserted-by":"publisher","first-page":"2946","DOI":"10.1038\/s41433-023-02445-8","volume":"37","author":"Y Attiku","year":"2023","unstructured":"Attiku Y, Nittala MG, Velaga SB, Ramachandra C, Bhat S, Solanki K, et al. Comparison of diabetic retinopathy severity grading on ETDRS 7-field versus ultrawide-field assessment. Eye (Lond). 2023;37(14):2946\u20139.","journal-title":"Eye (Lond)"},{"key":"4307_CR19","doi-asserted-by":"publisher","first-page":"3651","DOI":"10.2147\/OPTH.S275968","volume":"14","author":"A Moshfeghi","year":"2020","unstructured":"Moshfeghi A, Garmo V, Sheinson D, Ghanekar A, Abbass I. Five-year patterns of diabetic retinopathy progression in US clinical practice. Clin Ophthalmol. 2020;14:3651\u20139.","journal-title":"Clin Ophthalmol"},{"issue":"9","key":"4307_CR20","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1001\/jamaophthalmol.2021.2809","volume":"139","author":"DM Brown","year":"2021","unstructured":"Brown DM, Wykoff CC, Boyer D, Heier JS, Clark WL, Emanuelli A, et al. Evaluation of intravitreal aflibercept for the treatment of severe nonproliferative diabetic retinopathy: results from the PANORAMA randomized clinical trial. JAMA Ophthalmol. 2021;139(9):946\u201355.","journal-title":"JAMA Ophthalmol"},{"issue":"7","key":"4307_CR21","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1001\/jamaophthalmol.2021.0606","volume":"139","author":"RK Maturi","year":"2021","unstructured":"Maturi RK, Glassman AR, Josic K, Antoszyk AN, Blodi BA, Jampol LM, et al. Effect of intravitreous anti\u2013vascular endothelial growth factor vs sham treatment for prevention of vision-threatening complications of diabetic retinopathy: the Protocol W randomized clinical trial. JAMA Ophthalmol. 2021;139(7):701\u201312.","journal-title":"JAMA Ophthalmol"},{"issue":"4","key":"4307_CR22","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/S2213-8587(19)30411-5","volume":"8","author":"S Vujosevic","year":"2020","unstructured":"Vujosevic S, Aldington SJ, Silva P, Hernandez C, Scanlon P, Peto T, et al. Screening for diabetic retinopathy: new perspectives and challenges. Lancet Diabetes Endocrinol. 2020;8(4):337\u201347.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"4307_CR23","doi-asserted-by":"publisher","first-page":"e489","DOI":"10.1016\/S2214-109X(20)30488-5","volume":"9","author":"MJ Burton","year":"2021","unstructured":"Burton MJ, Ramke J, Marques AP, Bourne RRA, Congdon N, Jones I, et al. The Lancet Global Health Commission on Global Eye Health: vision beyond 2020. Lancet Glob Health. 2021;9(4):e489\u2013551.","journal-title":"Lancet Glob Health"},{"key":"4307_CR24","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s40662-015-0026-2","volume":"2","author":"R Lee","year":"2015","unstructured":"Lee R, Wong TY, Sabanayagam C. Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss. Eye Vis (Lond). 2015;2:17.","journal-title":"Eye Vis (Lond)"},{"key":"4307_CR25","unstructured":"World Health Organization. Diabetes. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/diabetes. 2022."},{"key":"4307_CR26","unstructured":"The International Diabetes Federation (IDF). Type 2 diabetes. https:\/\/idf.org\/about-diabetes\/diabetes-facts-figures\/. 2023."},{"key":"4307_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2021.108776","volume":"175","author":"S Shah","year":"2021","unstructured":"Shah S, Feher M, McGovern A, Sherlock J, Whyte MB, Munro N, et al. Diabetic retinopathy in newly diagnosed type 2 diabetes mellitus: prevalence and predictors of progression; a national primary network study. Diabetes Res Clin Pract. 2021;175:108776.","journal-title":"Diabetes Res Clin Pract"},{"issue":"23","key":"4307_CR28","doi-asserted-by":"publisher","first-page":"7083","DOI":"10.3390\/jcm13237083","volume":"13","author":"C Hern\u00e1ndez-Teixid\u00f3","year":"2024","unstructured":"Hern\u00e1ndez-Teixid\u00f3 C, de la Puente JB, Jimenez SM, Fernandez-Carmins A, Mauricio D, Aroca PR, et al. Incidence of diabetic retinopathy in individuals with type 2 diabetes: study using real-world data. J Clin Med. 2024;13(23):7083.","journal-title":"J Clin Med"},{"issue":"Suppl 1","key":"4307_CR29","doi-asserted-by":"publisher","first-page":"S203","DOI":"10.2337\/dc23-S012","volume":"46","author":"NA ElSayed","year":"2023","unstructured":"ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, et al. Retinopathy, neuropathy, and foot care: standards of care in diabetes-2023. Diabetes Care. 2023;46(Suppl 1):S203\u201315.","journal-title":"Diabetes Care"}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-025-04307-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12886-025-04307-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-025-04307-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T14:01:27Z","timestamp":1759759287000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcophthalmol.biomedcentral.com\/articles\/10.1186\/s12886-025-04307-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,6]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4307"],"URL":"https:\/\/doi.org\/10.1186\/s12886-025-04307-1","relation":{},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,6]]},"assertion":[{"value":"2 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the University of Oklahoma Health Sciences Center Institutional Review Board (#INV-001) and participants provided written informed consent prior to capture of photographs.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"GW: Advisor for Ocugen; honoraria from Genentech, Inc., Novartis, Regeneron. CCW: Consultant for Bayer; grant recipient from Genentech, Inc.\/Roche, Novartis, Regeneron. JB, VS, ZH: Employee of Genentech, Inc. and may be stakeholders in Roche. C-YL: Former employee of Genentech, Inc.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"547"}}